This article is more than 5 years old. Information may no longer be current.
FDA clears use of Cellvizio for robotic-assisted surgery
Click Here to Manage Email Alerts
Mauna Kea Technologies, inventor of Cellvizio, a multidisciplinary confocal laser endomicroscopy platform, has received FDA 510(k) clearance for its CelioFlex UHD Confocal Miniprobes for use with Cellvizio in robotic-assisted surgery procedures, according to a press release.
The CelioFlex UHD Confocal Miniprobes will provide visualization of body cavities, organs and canals during endoscopic and laparoscopic surgical procedures, said the release. These procedures include robotic-assisted surgery, which will enable doctors to perform many types of complex procedures with precision, flexibility and control, according to the release.
“This new FDA clearance is an important milestone for the company on its Cellvizio product roadmap and market expansion strategy,” Sacha Loiseau, PhD, founder and CEO of Mauna Kea Technologies, said. “We see the ability to instantaneously visualize and characterize tissue at the cellular level as a natural extension to robotic-assisted procedures and enabling data-driven surgery, which will in-part rely on advanced imaging and machine learning algorithms to provide reliable, real-time tissue information to surgeons.”
Disclosures: Loiseau is an employee of Mauna Kea Technologies.